The SAFE Study is to check the safety of using a medicine called aPCC following another medicine called emicizumab in people with Hemophilia A. Hemophilia A is a condition where blood doesn't clot properly because of a missing protein called factor VIII. This can cause bleeding in joints and tissues. APCC is a treatment to help blood clot. We'll see if we can use a test called a thrombin generation assay to give the right amount of aPCC during bleeding episodes.

• The study is for people 6 years and older with moderate hemophilia A.
• You can't take part if you've had bleeding or surgery recently.
• Your health, including liver and kidney function, should be good.

If you join, you might need to stop certain medications and will have regular check-ups. This study helps understand how to better treat bleeding in Hemophilia A patients taking emicizumab.